用于慢性丙型肝炎病毒感染的直接作用抗病毒药物。
Direct-acting antiviral medications for chronic hepatitis C virus infection.
作者信息
Jazwinski Alison B, Muir Andrew J
机构信息
Dr. Jazwinski is a Fellow and Dr. Muir is an Associate Professor in the Division of Gastroenterology and Duke Clinical Research Institute at Duke University Medical Center in Durham, North Carolina.
出版信息
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):154-62.
Abstract
Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of which have nonspecific and largely unknown mechanisms of action. New therapies are in development that act directly on the hepatitis C virus at various points in the viral life cycle. Published clinical trial data on these therapies are summarized in this paper. A new era of hepatitis C virus treatment is beginning, the ultimate goals of which will be directly targeting the virus, shortening the length of therapy, improving sustained virologic response rates, and minimizing side effects.
摘要
传统上，丙型肝炎病毒的治疗一直很困难，原因在于治疗成功率低，且因副作用导致治疗中断率高。目前的标准疗法包括聚乙二醇化干扰素α和利巴韦林，二者的作用机制均是非特异性的，且在很大程度上尚不明确。正在研发的新疗法可在病毒生命周期的不同阶段直接作用于丙型肝炎病毒。本文总结了关于这些疗法已发表的临床试验数据。丙型肝炎病毒治疗的新时代即将开启，其最终目标将是直接靶向病毒、缩短治疗疗程、提高持续病毒学应答率并将副作用降至最低。
相似文献
1
Direct-acting antiviral medications for chronic hepatitis C virus infection.用于慢性丙型肝炎病毒感染的直接作用抗病毒药物。
Gastroenterol Hepatol (N Y). 2011 Mar;7(3):154-62.
2
[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].[聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎病毒感染期间加用或不加用蛋白酶抑制剂直接抗病毒药物的副作用]
Orv Hetil. 2011 Dec 11;152(50):1997-2009. doi: 10.1556/OH.2011.29266.
3
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.直接作用抗病毒疗法治疗丙型肝炎病毒基因型 1 感染：一项多种治疗比较的荟萃分析。
QJM. 2013 Feb;106(2):153-63. doi: 10.1093/qjmed/hcs214. Epub 2012 Nov 17.
4
A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.一小部分丙型肝炎患者接受博赛泼维或特拉泼维的三联疗法。
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.
5
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.直接作用抗病毒药物和宿主靶向药物时代的慢性丙型肝炎病毒感染的治疗。
J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4.
6
Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.直接作用抗病毒治疗在退伍军人管理局治疗初治慢性 HCV 基因型 1 感染患者中的成本效益。
Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.
7
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.慢性丙型肝炎退伍军人应用直接作用抗病毒药物的早期病毒学应答和血液学安全性。
Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7. doi: 10.1016/j.cgh.2013.03.006. Epub 2013 Mar 21.
9
Advances in the treatment of hepatitis C virus infection.丙型肝炎病毒感染治疗的进展
Gastroenterol Hepatol (N Y). 2012 Feb;8(2):91-101.
10
Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.基于博赛泼维与特拉泼维的治疗方案用于治疗HIV/HCV合并感染患者的丙型肝炎病毒
Eur J Gastroenterol Hepatol. 2015 Feb;27(2):123-9. doi: 10.1097/MEG.0000000000000241.
引用本文的文献
1
6-Chlorocoumarin Conjugates with Nucleobases and Nucleosides as Potent Anti-Hepatitis C Virus Agents.6-氯香豆素与核碱基和核苷的缀合物作为强效抗丙型肝炎病毒剂
Molecules. 2025 Apr 15;30(8):1776. doi: 10.3390/molecules30081776.
2
Molecular docking analysis of fluoroquinolones and other natural and synthetic compounds with the HCV NS3 helicase.氟喹诺酮类药物以及其他天然和合成化合物与丙型肝炎病毒NS3解旋酶的分子对接分析
Bioinformation. 2022 Mar 31;18(3):147-154. doi: 10.6026/97320630018147. eCollection 2022.
3
Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors.新型双咪唑基苯基丁二炔衍生物作为丙型肝炎病毒NS5A抑制剂的设计与合成
Pharmaceuticals (Basel). 2022 May 20;15(5):632. doi: 10.3390/ph15050632.
4
'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.“全面治疗我这个人，而不仅仅是我的病情”：注射吸毒者的丙型肝炎护理提供偏好的定性探索。
Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.
5
In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.用于重新利用已批准抗病毒药物对抗SARS-CoV-2主要蛋白酶的计算机辅助分子对接分析。
Biochem Biophys Rep. 2021 Sep;27:101032. doi: 10.1016/j.bbrep.2021.101032. Epub 2021 Jun 3.
6
Hepatitis C virus modulates signal peptide peptidase to alter host protein processing.丙型肝炎病毒调节信号肽肽酶改变宿主蛋白加工。
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22). doi: 10.1073/pnas.2026184118.
7
In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach.利用分子建模方法寻找可缓解宿主针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的固有免疫反应抑制的药物。
In Silico Pharmacol. 2021 Apr 4;9(1):26. doi: 10.1007/s40203-021-00085-y. eCollection 2021.
8
Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine.丙型肝炎病毒的发现：2020年诺贝尔医学奖。
Euroasian J Hepatogastroenterol. 2020 Jul-Dec;10(2):105-108. doi: 10.5005/jp-journals-10018-1326.
9
Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?抗病毒治疗对丙型肝炎后肝硬化患者的疗效：高尿酸血症是一种潜在的不良反应吗？
BMJ Open Gastroenterol. 2020 Dec;7(1). doi: 10.1136/bmjgast-2020-000533.
10
Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment-ADVANCE HCV protocol study.在注射设备提供点进行的随机对照试验，比较不同丙型肝炎治疗方案在注射毒品人群中的疗效：直接观察治疗与每两周收集一次的 HCV 治疗 ADVANCE HCV 方案研究。
BMJ Open. 2019 Aug 8;9(8):e029516. doi: 10.1136/bmjopen-2019-029516.
本文引用的文献
1
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.Boceprevir，一种 NS3 蛋白酶抑制剂，联合聚乙二醇干扰素 alfa-2b 和利巴韦林治疗初治基因 1 型丙型肝炎感染患者的疗效（SPRINT-1）：一项开放标签、随机、多中心 2 期临床试验。
Lancet. 2010 Aug 28;376(9742):705-16. doi: 10.1016/S0140-6736(10)60934-8. Epub 2010 Aug 6.
2
Telaprevir for previously treated chronic HCV infection.替拉瑞韦治疗既往治疗的慢性 HCV 感染。
N Engl J Med. 2010 Apr 8;362(14):1292-303. doi: 10.1056/NEJMoa0908014.
3
Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.从艾滋病毒治疗中吸取的经验教训应用于病毒性肝炎治疗：研讨会总结。
Am J Gastroenterol. 2010 May;105(5):989-1004; quiz 988, 1005. doi: 10.1038/ajg.2009.726. Epub 2010 Jan 19.
4
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.白细胞介素28B的基因变异可预测丙型肝炎治疗诱导的病毒清除情况。
Nature. 2009 Sep 17;461(7262):399-401. doi: 10.1038/nature08309. Epub 2009 Aug 16.
5
Monoclonal and polyclonal antibodies against the HCV envelope proteins.针对丙型肝炎病毒包膜蛋白的单克隆抗体和多克隆抗体。
Clin Liver Dis. 2009 Aug;13(3):477-86. doi: 10.1016/j.cld.2009.05.011.
6
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.聚乙二醇干扰素α-2b或α-2a联合利巴韦林用于治疗丙型肝炎感染。
N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22.
7
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.特拉匹韦与聚乙二醇干扰素联合或不联合利巴韦林用于慢性丙型肝炎病毒感染的治疗。
N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650.
8
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.特拉匹韦联合聚乙二醇干扰素和利巴韦林用于慢性丙型肝炎1型感染
N Engl J Med. 2009 Apr 30;360(18):1827-38. doi: 10.1056/NEJMoa0806104.
9
Diagnosis, management, and treatment of hepatitis C: an update.丙型肝炎的诊断、管理与治疗：最新进展
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
10
Evidence of recombination in intrapatient populations of hepatitis C virus.丙型肝炎病毒患者体内种群中重组的证据。
PLoS One. 2008 Sep 18;3(9):e3239. doi: 10.1371/journal.pone.0003239.
Zotero 插件